OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Mehmi on Fianlimab and Cemiplimab in Patients with Poor-Risk, Advanced Melanoma

August 17th 2023

Inderjit Mehmi, MD, discusses results from a subgroup analysis of patients with advanced melanoma and poor-risk features given fianlimab and cemiplimab in a phase 1 trial.

Dr Santos on the ADAURA Trial of Adjuvant Osimertinib in EGFR-Mutant NSCLC

August 17th 2023

Edgardo S. Santos, MD, FACP, discusses key survival data from the pivotal phase 3 ADAURA trial in early-stage non–small cell lung cancer.

Dr Kopetz on the Investigation of Encorafenib, Cetuximab, and Chemotherapy in mCRC

August 16th 2023

Scott Kopetz, MD, PhD, FACP, discusses the phase 3 BREAKWATER trial in patients with BRAF V600E–mutant metastatic colorectal cancer.

Dr Williams on the Importance of Investigating ADCs in Ovarian Cancer

August 16th 2023

Heather R. Williams, MD, discusses the importance of further exploring the use of antibody drug conjugates in ovarian cancer, specifically highlighting the investigation of mirvetuximab soravtansine in this population.

Dr Schinke on the Rationale for the MonumenTAL-1 Trial in Multiple Myeloma

August 16th 2023

Carolina D. Schinke, MD, discusses the rationale for conducting the phase 1/2 MonumenTAL-1 trial in patients with multiple myeloma.

Dr Massarelli on Addressing Unmet Needs in SCLC

August 16th 2023

Erminia Massarelli, MD, PhD, MS, discusses unmet needs in the treatment of patients with small cell lung cancer that were discussed at the 2023 Bridging the Gaps in Lung Cancer meeting, as well as how further research may help mitigate these needs.

Franklin on Strategies to Ameliorate the Effect of Social Determinants on CRC Screening Rates

August 16th 2023

Isabelle Franklin, discusses strategies healthcare providers can implement to address or ameliorate disparities in place that are affecting screening rates in colorectal cancer.

Dr Dholaria on Ongoing Investigations of Talquetamab and Daratumumab in R/R Multiple Myeloma

August 16th 2023

Bhagirathbhai Dholaria, MBBS, discusses next steps for investigating subcutaneous talquetamab and daratumumab in relapsed/refractory multiple myeloma based on data from the phase 1 TRIMM-2 trial.

Dr Patel on Maintaining Quality of Life While Treating Patients With Multiple Myeloma

August 15th 2023

Krina K. Patel, MD, MSc, discusses maintaining quality of life while treating patients with multiple myeloma, as well as highlights from the phase 3 KarMMa-3 trial.

Dr Masarova on the Investigation of Ropeginterferon Alfa in Essential Thrombocythemia

August 15th 2023

Lucia Masarova, MD, discusses the investigation of ropeginterferon alfa in adult patients with essential thrombocythemia, highlighting the unmet needs that investigators aim to address with this investigation.

Franklin on Future Steps for Investigating the Association Between Social Needs and CRC Screening Rates

August 15th 2023

Isabelle Franklin, discusses future steps to be taken following an investigation into the association between self-reported social needs and colorectal cancer screening rates.

Dr Hitchins on the Association Between Constitutional MLH1 Methylation and MRD in Select Cancers

August 15th 2023

Megan Hitchins, PhD, discusses results from an analysis on the prevalence of high-risk constitutional MLH1 methylation in early-onset colorectal and endometrial cancers displaying mismatch repair deficiency.

Dr Spira on the Ongoing Investigation of MYTX-011 in NSCLC

August 15th 2023

Alexander I. Spira, MD, PhD, FACP, discusses a phase 1 study of the antibody-drug conjugate MYTX-011 in patients with non–small cell lung cancer.

Dr Chari on the FDA Approval of Talquetamab in Relapsed/Refractory Multiple Myeloma

August 14th 2023

Ajai Chari, MD, discusses the significance of the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma.

Dr Alumkal on the Effects of the ARESENS Trial on the Treatment of mHSPC

August 14th 2023

Joshi Alumkal, MD, discusses the effects of the phase 3 ARESENS trial on the treatment of metastatic hormone-sensitive prostate cancer.

Dr Sonpavde on the Future of Treating Bladder Cancer

August 14th 2023

Guru P. Sonpavde, MD, discusses the future of bladder cancer treatment, including potential novel targets and further research with immunotherapy and antibody-drug conjugates.

Dr Qin on Choosing Between Targetable Agents in EGFR Exon 20–Mutated Lung Cancer

August 14th 2023

Angel Qin, MD, discusses her process when choosing between targetable agents for patients with EGFR exon 20–mutated lung cancer.

Dr Conlin on CDK4/6 Inhibitor Sequencing and QOL in Breast Cancer

August 11th 2023

Alison K. Conlin, MD, discusses unanswered questions regarding the use of CDK4/6 inhibitors after prior progression on CDK4/6 inhibitors and quality of life considerations in patients with breast cancer.

Dr Langer on Encorafenib Plus Binimetinib in BRAF V600E–Mutant NSCLC

August 11th 2023

Corey J. Langer, MD, discusses findings from the ongoing phase 2 PHAROS trial in patients with non–small cell lung cancer harboring BRAF V600E mutations.

Dr Blakely on the Rationale for Investigating Neoadjuvant Osimertinib in EGFR-Mutated NSCLC

August 10th 2023

Collin Blakely, MD, PhD, discusses a phase 2 trial evaluating the use of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutated non-small cell lung cancer, findings from which were presented at the 2023 ASCO Annual Meeting.